- Home
- BTOG vs QLGN Comparison
BTOG vs QLGN Comparison
Compare BTOG & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTOG
- QLGN
- Stock Information
- Founded
- BTOG 2018
- QLGN 1996
- Country
- BTOG Singapore
- QLGN United States
- Employees
- BTOG N/A
- QLGN N/A
- Industry
- BTOG Finance: Consumer Services
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- BTOG Finance
- QLGN Health Care
- Exchange
- BTOG Nasdaq
- QLGN Nasdaq
- Market Cap
- BTOG 2.0M
- QLGN 2.4M
- IPO Year
- BTOG 2019
- QLGN N/A
- Fundamental
- Price
- BTOG $0.15
- QLGN $3.32
- Analyst Decision
- BTOG
- QLGN
- Analyst Count
- BTOG 0
- QLGN 0
- Target Price
- BTOG N/A
- QLGN N/A
- AVG Volume (30 Days)
- BTOG 51.6M
- QLGN 111.5K
- Earning Date
- BTOG 01-01-0001
- QLGN 04-15-2025
- Dividend Yield
- BTOG N/A
- QLGN N/A
- EPS Growth
- BTOG N/A
- QLGN N/A
- EPS
- BTOG N/A
- QLGN N/A
- Revenue
- BTOG $2,888,482.00
- QLGN N/A
- Revenue This Year
- BTOG N/A
- QLGN N/A
- Revenue Next Year
- BTOG N/A
- QLGN N/A
- P/E Ratio
- BTOG N/A
- QLGN N/A
- Revenue Growth
- BTOG N/A
- QLGN N/A
- 52 Week Low
- BTOG $0.16
- QLGN $2.96
- 52 Week High
- BTOG $5.73
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- BTOG 34.83
- QLGN 44.88
- Support Level
- BTOG $0.25
- QLGN $3.06
- Resistance Level
- BTOG $0.20
- QLGN $3.78
- Average True Range (ATR)
- BTOG 0.02
- QLGN 0.28
- MACD
- BTOG -0.00
- QLGN 0.03
- Stochastic Oscillator
- BTOG 2.57
- QLGN 19.80
About BTOG Bit Origin Limited
Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.